Arix Bioscience
OverviewSuggest Edit
Arix Bioscience is a provider of venture capital funding services intended to build international group of healthcare and life science businesses. Its services encourage investment in early-stage companies by offering tax benefits in return for the additional risks involved, providing both start-up and later-stage companies with specialized fund management service.
| Type | Public | |
| Founded | 2015 | |
| HQ | London, GB | Map |
| Website | arixbioscience.com |
Recent NewsAll News
- Arix Bioscience plc: Arix to Present at the Proactive One2One Biotech Forum
- Arix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United States
- Arix Bioscience plc: 2019 Capital Markets Day
- Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
Key People/Management at Arix Bioscience
Naseem Amin
Executive Chairman
Robert Lyne
Chief Operating Officer and General Counsel
Jonathan Tobin
Managing Director
Mark Chin
Investment Director
Ed Rayner
Investment Director
Marcus Karia
Group Finance Director
Arix Bioscience Office Locations
Arix Bioscience has an office in London
London, GB (HQ)
20 Berkeley Square, Mayfair
Arix Bioscience Financials and Metrics
Arix Bioscience Revenue
Arix Bioscience's revenue was reported to be £1.33 m in FY, 2018
| GBP | |
|---|---|
Revenue (FY, 2018) | 1.3m |
Net income (FY, 2018) | 36.9m |
EBIT (FY, 2018) | 40.8m |
Market capitalization (26-Jun-2020) | 117.3m |
Closing stock price (26-Jun-2020) | 86.5 |
Cash (31-Dec-2018) | 91.2m |
EV | 26.0m |
Arix Bioscience's current market capitalization is £117.3 m.
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Revenue | 1.9m | 1.3m |
Depreciation and amortization | 218.0k | 216.0k |
EBIT | (3.6m) | 40.8m |
EBIT margin, % | (193%) | 3073% |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash | 74.9m | 91.2m |
Accounts Receivable | 275.0k | 1.7m |
Current Assets | 76.2m | 93.4m |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash From Operating Activities | (8.8m) | (11.1m) |
Cash From Investing Activities | (50.2m) | (115.4m) |
Cash From Financing Activities | 105.1m | 82.2m |
Net Change in Cash | 46.0m | (44.2m) |
| GBP | FY, 2017 |
|---|---|
Revenue/Employee | 137.6k |
Financial Leverage | 1 x |
Arix Bioscience Cybersecurity Score
Arix Bioscience Online and Social Media Presence
Arix Bioscience's Trends
Arix Bioscience News and Updates
June 09, 2020
Arix Bioscience plc: Arix to Present at the Proactive One2One Biotech Forum
LONDON, June 9, 2020 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Jonathan Tobin, PhD, Managing Director, will present at the Proactive One2One Virtual...
February 17, 2020
Arix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United States
LONDON, Feb. 17, 2020 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that one of its portfolio companies, Imara Inc., ("Imara"), has filed a...
October 03, 2019
Arix Bioscience plc: 2019 Capital Markets Day
LONDON, Oct. 3, 2019 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, is hosting its 2019 Capital Markets Day from 1:45pm today Thursday, 3rd October 2019 in London. The Capital...
September 30, 2019
Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
LONDON, Sept. 30, 2019 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has invested in new portfolio company STipe Therapeutics ("STipe"), a company...
September 17, 2019
Arix Bioscience plc: Amplyx Unveils Expanded Pipeline and Reports Phase 2 Data from Lead Programme
LONDON, Sept. 17, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes the following updates from its portfolio company Amplyx Pharmaceuticals ("Amplyx"), a biotech...
September 13, 2019
Arix Bioscience plc - Imara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering in the United States
LONDON, Sept. 13, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company Imara, Inc. ("Imara"), has confidentially submitted a draft...
Arix Bioscience Blogs
October 01, 2018
Co-leads $58 million Series A investment round for VelosBio
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio[1] to 15 companies Arix commits $11 million (£8.4 million)[2] for 11.2% owner…
September 26, 2018
LogicBio files registration for proposed IPO in the US
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 26 September 2018: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, announces that o…
September 18, 2018
Update on Iterum Therapeutics Phase 3 trials
LONDON, 18 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Iterum Therapeutics plc (“Iterum”) (Nasdaq: ITRM) has initiated the remaining two of three planned Phase 3 pivo…
September 13, 2018
ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 12 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur…
September 04, 2018
Changes announced to executive team to accelerate growth and strategy
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 4 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces planned changes to its execut…
August 06, 2018
Arix Bioscience announces first VIPE investment
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company adv…
Arix Bioscience Frequently Asked Questions
When was Arix Bioscience founded?
Arix Bioscience was founded in 2015.
Who are Arix Bioscience key executives?
Arix Bioscience's key executives are Naseem Amin, Robert Lyne and Jonathan Tobin.
How many employees does Arix Bioscience have?
Arix Bioscience has 15 employees.
What is Arix Bioscience revenue?
Latest Arix Bioscience annual revenue is £1.3 m.
What is Arix Bioscience revenue per employee?
Latest Arix Bioscience revenue per employee is £88.5 k.
Who are Arix Bioscience competitors?
Competitors of Arix Bioscience include Juvenescence, Omega Healthcare Investors and Mobilion Systems.
Where is Arix Bioscience headquarters?
Arix Bioscience headquarters is located at 20 Berkeley Square, Mayfair, London.
Where are Arix Bioscience offices?
Arix Bioscience has an office in London.
How many offices does Arix Bioscience have?
Arix Bioscience has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies